XASE
IBO
Market cap5mUSD
Jul 09, Last price
0.45USD
1D
0.18%
1Q
-34.21%
IPO
-80.58%
Name
Impact Biomedical Inc
Chart & Performance
P/E
—
P/S
162.67
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.36%
Rev. gr., 5y
%
Revenues
32k
-98.02%
Net income
-12m
L+730.36%
CFO
-2m
L-66.46%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||